Document:

Amendment to Executive Employment Agreement with Edward Solomon

 Exhibit 10.13 
 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT 
 This Amendment to Executive Employment Agreement (the
“Amendment”) is entered into as of July 2, 2009, by and between NovaRay Medical, Inc., a Delaware corporation with its principal place of business at 39655 Eureka Drive, Newark, California 94560 (“Company”) and Edward G.
Solomon (“Executive”) (collectively, the “parties”). All capitalized terms not otherwise defined herein shall have the meaning ascribed to them in that certain Executive Employment Agreement dated as of December 19, 2007
with Executive (the “Agreement”). 
 RECITALS 
 WHEREAS, the Company and Executive entered into the Agreement; 
 WHEREAS, the Company and Executive desire to amend the Agreement to be as set
forth herein. 
 NOW, THEREFORE, in compliance with Section 16 of the Agreement and in consideration of the mutual promises and covenants set forth
herein and in the Agreement and Statement of Work, the Client and the Company hereby agree as follows: 
 Section 2.3 of the Agreement is herby amended
to read in its entirety: 
 Work Location. Executive’s principal place of work shall be located in Newark, at Company’s offices.

 Section 4.1 of the Agreement is hereby amended to read in its entirety: 
 “Salary. As compensation for the proper and satisfactory performance of all duties to be performed by Executive hereunder, Company shall pay to Executive a base salary of $285,000.00 per year, less
applicable withholdings (the “Base Salary”). Until the receipt of gross proceeds from equity or debt or other financing obtained by Company of at least Five Million Dollars ($5,000,000) in the aggregate after July 7, 2009, eighty
percent (80%) of the Base Salary or $9,500 for each applicable semi-monthly pay period, less applicable withholdings, shall be paid in accordance with the Company’s regularly established payroll practice. The remaining $2,375 for each
applicable semi-monthly pay period, less applicable withholdings, shall be paid in the event of (i) a receipt of gross proceeds from equity or debt or other financing obtained by Company of at least Five Million Dollars ($5,000,000) in the
aggregate after July 7, 2009, (ii) a termination of 

 
Executive’s employment under the Agreement by the Company without Cause or (iii) a termination of Executive’s employment under the Agreement
by Executive for Good Reason. After the receipt of gross proceeds from equity or debt or other financing obtained by Company of at least Five Million Dollars ($5,000,000) in the aggregate after July 7, 2009, the Base Salary shall be paid in
accordance with the Company’s regularly established payroll practice. In the event Executive’s employment under this Agreement is terminated by either party, for any reason, Executive will be entitled to receive such amount of his salary
earned as provided in this Section through the date of such termination.” 
 Section 4.2 of the Agreement is hereby amended to read in its
entirety: 
 Incentive Compensation. 
  

	 	(a)	Discretionary Incentive Compensation. Executive may be granted incentive compensation in the Company’s discretion. If Company, in its sole and absolute discretion,
grants Executive incentive compensation, the terms, amount and payment of such incentive compensation will be determined solely by Company. Such incentive compensation may be payable in either cash or stock of the Company or any combination thereof
at the election of the Company and pursuant to terms and conditions established by the Board of Directors of the Company. 

  

	 	(b)	Debt or Equity Financing. In the event the Company receives aggregate gross proceeds not less than $3,000,000 from debt or equity financings after July 7, 2009 and prior
to December 31, 2010 (excluding proceeds from funds managed by Vision Capital Advisors, LLC), Executive shall receive incentive compensation set forth in Section 4.3(c) below for raising such additional debt or equity financing provided
that Executive is employed with the Company at the time of such receipt of gross proceeds. 

  

	 	(c)	 Calculation. The method described in this section are to be used as guidelines for determining such incentive compensation. The Board of Directors of the
Company in its sole and absolute discretion may adjust percentages up or down based on the terms of such debt or equity financing transaction. In the event the Company receives aggregate gross proceeds not less than $3,000,000 from equity financings
after July 7, 2009 and prior to December 31, 2010 (excluding proceeds from funds managed by Vision Capital Advisors, LLC), such compensation will be initially based on a percentage of Executive’s base salary listed in Table 1 below
taking into account the amount raised and the pre-money valuation. In the event the Company receives aggregate gross proceeds not less than $3,000,000 from straight debt financings after July 7, 2009 and prior to December 31, 2010
(excluding proceeds from funds managed by Vision Capital Advisors, LLC), such compensation will be initially 

	 	 
based on a percentage of Executive’s base salary listed in the $80M pre-money valuation row in Table 1 below. In the event the Company receives
aggregate gross proceeds not less than $3,000,000 from convertible debt financings after July 7, 2009 and prior to December 31, 2010 (excluding proceeds from funds managed by Vision Capital Advisors, LLC), such compensation will be
initially based on a percentage of Executive’s base salary listed in Table 1 below taking into account the amount raised and the pre-money valuation assuming conversion of such convertible debt. In the event such converted pre-money valuation
is unknown, the Board of Directors of the Company will determine the appropriate percentage. Such incentive compensation may be payable in either (i) cash or (ii) a combination of cash and up to 60 to 70% of such incentive compensation in
Incentive Stock Options issued pursuant to the Company’s 2008 Stock Incentive Plan in lieu of cash with the value of such options determined by the Black Scholes valuation method used the Company to value stock options in its audited financial
statements. 

 Table 1 
 Valuation Percentage 
  

													
	Premoney Valuation $M	  	Amount Raised $M	 
	 	  	$3	 	 	$5	 	 	$7.50	 	 	$10	 
	 $30
	  	9	% 	 	15	% 	 	21	% 	 	24	% 
	 $40
	  	12	% 	 	20	% 	 	28	% 	 	32	% 
	 $50
	  	15	% 	 	25	% 	 	35	% 	 	40	% 
	 $60
	  	20	% 	 	33	% 	 	48	% 	 	60	% 
	 $70
	  	25	% 	 	41	% 	 	61	% 	 	80	% 
	 $80+
	  	30	% 	 	50	% 	 	75	% 	 	100	% 
	 or straight debt
	  			 			 			 		

 Section 4.3 of the Agreement is hereby amended to read in its entirety: 
 Stock Options. Executive may be granted stock options from time to time in the discretion of Company subject to the terms and conditions of a Company
approved stock option plan and pursuant to the stock option agreement under which such options are granted. Provided that Company has not terminated Executive’s employment for Cause and Executive has not terminated his employment other than for
Good Reason, the Company shall grant Executive an option to purchase 275,000 shares of the Common Stock of the Company upon receipt of gross proceeds from equity or debt or other financing obtained by Company of at least Five Million Dollars
($5,000,000) in the aggregate after July 7, 2009. Such option shall be immediately vested, have an exercise 

 
price equal to the then current fair market value of such Common Stock, have a ten year term and be subject to the terms of the Company’s 2008 Stock
Incentive Plan and the terms of the form of Stock Option Agreement under such plan.” 
 Section 7.2 of the Agreement is hereby amended to read in
its entirety: 
 “Termination Without Cause By Company/Severance. Company may terminate Executive’s employment under this Agreement
without Cause at any time. In the event of such termination, Executive will receive the Standard Entitlements plus the following Severance Pay: (a) twelve (12) months of Executive’s Base Salary then in effect on the date of
termination, payable in the form of salary continuation, and twelve (12) months of Executive’s health care benefits then in effect on the date of termination provided the cost to the Company of such health care benefits does not exceed the
cost in effect on the date of termination and for such salary continuation and such health care benefits (the “Severance Pay”) and (b) the vesting of any stock options held by Executive at the time of such termination will accelerate
as to the number of shares that otherwise would have vested and been exercisable as of the date that is twenty-four (24) months from the date of termination. The Severance Pay will be payable in accordance with Company’s regular payroll
cycle. Executive’s receipt of the Severance Benefits will be contingent upon: (x) Executive’s compliance with all surviving provisions of this Agreement as specified in subparagraph 15.7 below; (y) Executive’s execution of a
full general release in a form provided by the Company, releasing all claims, known or unknown, that Executive may have against Company arising out of or any way related to Executive’s employment or termination of employment with Company; and
(z) Executive’s agreement to act as a consultant for Company for up to a maximum of sixty (60) calendar days immediately following the date of termination, without additional compensation, if requested to do so by Company. All other
Company obligations to Executive pursuant to this Agreement will become automatically terminated and completely extinguished.” 
 Section 7.3 of
the Agreement is hereby amended to read in its entirety: 
 “Voluntary Resignation By Executive. Executive may voluntarily resign
Executive’s position with Company at any time on thirty (30) days advance written notice. The Company shall have the option, in its sole discretion, to make Executive’s termination effective at any time prior to the end of such notice
period as long as the Company pays Executive the amount provided in Section 4.1 above through the last day of the thirty (30) day notice period. In the event of Executive’s resignation, Executive shall be entitled to receive only the
(i) the amount provided in Section 4.1 above, earned through the date of such termination, (ii) benefits coverage through the date of such termination, and (iii) reimbursement of business expenses properly incurred prior to the
date of such termination and submitted in accordance with the Company’s policies. All other 

 
Company obligations to Executive pursuant to this Agreement will become automatically terminated and completely extinguished. In addition, in the event
Executive resigns from his employment with the Company, Executive will not be entitled to receive the Severance Pay described in Section 7.2 herein. 
 The Company and Executive hereby acknowledge and consent to the foregoing amendments to the Agreement as set forth herein. 
 Except as amended
herein, all other terms and provisions of the Agreement shall remain in full force and effect. 
 This Amendment shall be effective upon its execution by the
Company and Executive. 
 This Amendment may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and
all of which taken together shall constitute one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other parties hereto, it being understood that all parties need not sign the
same counterpart. In the event that any signature is delivered by facsimile or electronic transmission, such signature shall create a valid binding obligation of the party executing (or on whose behalf such signature is executed) the same with the
same force and effect as if such facsimile or electronic signature were the original thereof. 
 IN WITNESS WHEREOF, the parties have duly executed this
Amendment as of the date first written above. 
  

					
	Dated: July 2, 2009	 	 /s/ Edward G. Solomon

		 	Edward G. Solomon
		
	Dated: July 2, 2009	 	NovaRay Medical, Inc.
			
		 	By:	 	 /s/ Marc C. Whyte

		 		 	Marc C. Whyte
		 		 	 Chief Executive Officer
 NovaRay Medical,
Inc.Specimen Common Stock Certificate

 Exhibit 4.3 
 RENASANT CORPORATION 
 TUPELO, MISSISSIPPI 
 INCORPORATED UNDER THE LAWS 
 OF THE
STATE OF MISSISSIPPI 
  
  
 CUSIP 79570E-10-7 
 SEE REVERSE SIDE 

FOR CERTAIN DEFINITIONS 
 THIS CERTIFIES THAT
                             IS THE OWNER OF
                             FULLY PAID AND NON-ASSESSABLE SHARES OF THE CAPITAL STOCK, PAR VALUE
$5.00 PER SHARE, OF RENASANT CORPORATION transferable only on the books of the Company by the holder hereof in person or by duly authorized attorney, on surrender of this certificate properly endorsed. 
 This Certificate is not valid unless countersigned by the Transfer Agent and registered by the Registrar. 
 WITNESS the facsimile seal of the Company and the facsimile signatures of its duly authorized officers. 
  

									
	Dated:	 	 	 		 	

									
			
	/s/ Steve Corban	 		 	/s/ E. Robinson McGraw
	Secretary	 		 	President

 The Company will furnish to any shareholder upon request and without charge a full statement of the designation, relative
rights, preferences and limitations of the shares of each class authorized to be issued and the designation, relative rights, preferences and limitations of each series of preferred shares which the Company is authorized to issue so far as the same
have been fixed, and the authority of the Board of Directors of the Company to designate and fix the relative rights, preferences and limitations of other series. 
 The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: 
  

											
	 TEN COM—as tenants in common
 TEN ENT—as tenants by the entireties
 JT TEN—as joint tenants with right of survivorship and not as tenants in common
	 		 	UNIF GIFT MIN ACT -	 	 	 	Custodian	 	 
	 		 		 	(Cust.)	 		 	(Minor)
	 		 		 	under Uniform Gifts to Minors
				
		 		 		 	 
		 		 		 	(State)

 Additional abbreviations may also be used though not in the above list. 
 For value received,
                             hereby sell, assign and transfer unto 
  
  
 (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE) 
  
  
  
  
                                        
                                      shares of the capital
stock represented by the within Certificate, and do hereby irrevocably constitute and appoint
                                         
                                Attorney to transfer the said stock on the books of the
within named Corporation with full power of substitution in the premises. 
  

									
					
	Dated	 	 	 		 		 	 
		 		 		 		 	Signature(s)

 NOTICE: THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE OF THE CERTIFICATE
IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT, OR ANY CHANGE WHATEVER. 
 Signature(s) Guaranteed: 
  
  
 THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM), PURSUANT TO SEC RULE
17AD-15.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00160-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00160-of-00352.parquet"}]]